BEZ235
Phase 2Terminated 1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoma Transitional Cell
Conditions
Carcinoma Transitional Cell
Trial Timeline
Feb 1, 2013 → Jan 1, 2014
NCT ID
NCT01856101About BEZ235
BEZ235 is a phase 2 stage product being developed by Novartis for Carcinoma Transitional Cell. The current trial status is terminated. This product is registered under clinical trial identifier NCT01856101. Target conditions include Carcinoma Transitional Cell.
What happened to similar drugs?
20 of 20 similar drugs in Carcinoma Transitional Cell were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01856101 | Phase 2 | Terminated |
| NCT01690871 | Phase 2 | Withdrawn |
| NCT01288092 | Phase 2 | Withdrawn |
| NCT01290406 | Phase 2 | Withdrawn |
| NCT01453595 | Phase 1/2 | Terminated |
| NCT01343498 | Phase 1 | Completed |
| NCT01195376 | Phase 1 | Completed |
| NCT00620594 | Phase 1 | Completed |
Competing Products
20 competing products in Carcinoma Transitional Cell